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ABSTRACT
Objectives Palliative care (PC) services and
patients differ across countries. Data on PC
delivery paired with medical and self-reported
data are seldom reported. Aims were to describe
(1) PC organisation and services in participating
centres and (2) characteristics of patients in PC
programmes.
Methods This was an international prospective
multicentre study with a single web-based survey
on PC organisation, services and academics and
patients’ self-reported symptoms collected at
baseline and monthly thereafter, with concurrent
registrations of medical data by healthcare
providers. Participants were patients ≥18 enrolled
in a PC programme.
Results 30 centres in 12 countries participated;
24 hospitals, 4 hospices, 1 nursing home,
1 home-care service. 22 centres (73%) had PC
in-house teams and inpatient and outpatient
services. 20 centres (67%) had integral
chemotherapy/radiotherapy services, and most
(28/30) had access to general medical or
oncology inpatient units. Physicians or nurses
were present 24 hours/7 days in 50% and 60%
of centres, respectively. 50 centres (50%) had
professorships, and 12 centres (40%) had full-
time/part-time research staff. Data were available
on 1698 patients: 50% females; median age 66
(range 21–97); median Karnofsky score 70 (10–
100); 1409 patients (83%) had metastatic/
disseminated disease; tiredness and pain in the
past 24 hours were most prominent. During
follow-up, 1060 patients (62%) died; 450 (44%)
<3 months from inclusion and 701 (68%) within
6 months. ANOVA and χ2 tests showed that
hospice/nursing home patients were significantly
older, had poorer performance status and had
shorter survival compared with hospital-patients
(p<.0.001).
Conclusions There is a wide variation in PC
services and patients across Europe. Detailed
characterisation is the first step in improving PC
services and research.
Trial registration number ClinicalTrials.gov
Identifier: NCT01362816.
INTRODUCTION
The WHO definition of palliative care
(PC) states that it should be available
early in the disease trajectory and may be
delivered alongside potentially curative
treatments.1 However, only 1 in 10 of
those who need PC receive it.2
One reason for this may be that PC has
often been misconstrued as end-of-life
care3 and consequently referrals occur
too late. A retrospective study showed
that referrals took up to 16 months after
being diagnosed with advanced cancer,
with a median interval between the PC
consultation and death of 1.4 months.4
However, there is now a persuasive argu-
ment that introducing PC early in
patients with advanced disease has bene-
ficial effects on physical symptoms, psy-
chological distress, prognostication and
survival.5–7
Despite the positive development of
palliative care units (PCUs) and PC spe-
cialist training for doctors and nurses,8
the integration of PC and oncology
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services varies widely. Furthermore, establishing PC as
an academic field in its own right has progressed
slowly.9 Recently, two large-scale European
Commission funded projects, IMPACT (http://www.
impactpalliativecare.eu/) and EURO IMPACT (http://
www.euro-impact.eu/), have developed a set of recom-
mendations for policymakers and decision-makers to
help improve the quality of and access to PC in an
ageing Europe,10 focusing on improving the quality of
care at all levels and that specialist PC services should
be available in all healthcare settings.
The first step in meeting these recommendations is
to characterise PC services and their patients across
multiple centres, settings and countries in Europe. To
this end, the European Palliative Care Cancer
Symptom study (EPCCS) was developed, supported
by the European Association for Palliative Care
(EAPC) Research Network (http://www eapcrn.org/)
and the European Palliative Care Research Centre
(http://www.ntnu.edu/prc/).
We present here the main report from the EPCCS
study, which describes the organisation and delivery of
PC at specific centres across Europe. The key clinical
characteristics of the patients at these centres are also
described.
MATERIALS AND METHODS
Invitations to participate were distributed to
EAPC-RN and PRC members and advertised at EAPC
conferences.
The data collection consisted of three parts:
A. Assessment of PC service: a single web survey on organ-
isational and economic issues
B. Registration of patients’ medical data using a case report
form completed by the healthcare providers (HCP-CRF)
at each patient encounter
C. Patients’ self-reported data (patient-CRF) completed at
each patient encounter.
All forms were forward-backward translated into
the language of the participating centre.
Assessment of PC service
A one-time registration of institutional data was done
using an English language web-based survey. This was
completed in 2010 before any patients were included.
The survey consisted of four parts covering (1) institu-
tion details; for example, type of hospital, size and
catchment area, (2) description of the PC programme;
for example, size, composition, types of PC services
and anti-cancer treatment, (3) organisational issues
and academic affiliations and (4) funding sources.
The healthcare provider-CRF
The HCP-CRF consisted of a brief set of medical and
treatment-related variables, informed by the EAPC
basic data set that was under development at the
time,11 a four-item version of the mini-mental state
examination (MMSE),12 using the suggested cut-off of
four (of maximum eight) to indicate possible cognitive
failure,13 and the Karnofsky Performance Status
Scale.14 A retrospective recording of date of death was
performed in February 2014, ∼6 months after inclu-
sion of the last patients.
The patient CRF
The patient CRF consisted of key sociodemographic
items: age, sex, education and living situation and
questions about common cancer-related symptoms.
This included two items from the Brief Pain Inventory
(BPI)15 average and worst pain intensity during the
past 24 hours, to be answered on a 0–10 numerical
rating scale, two dichotomous questions on neuro-
pathic pain (NP) symptoms (skin sensitivity/numbness)
and breakthrough pain (BTP) adapted from Pain
Detect16 and the Alberta Breakthrough Pain
Assessment Tool,17 respectively. Depression was
assessed by the two items on anhedonia and depressed
mood from the Brief Patient Health Questionnaire-
PHQ9,18 corresponding to the main items in the
DSM-5 criteria for depression and assessing the fre-
quency at which they have been bothersome during
the past 2 weeks: 0=‘not at all’, 1=‘several days’,
2=‘more than half the days’ and 3=‘nearly every day’.
Furthermore, the revised version of the Edmonton
Symptom Assessment System (ESAS-r)19 and the PC
version of the European Organisation for Research
and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C15-PAL)20 were used.
The physical function scale of the QLQ-C15-PAL was
scored from 1: ‘not at all’ to 4 ‘very much’ trans-
formed to a 0–100 scale.
PATIENTS AND SAMPLING
Eligible patients were: enrolled in the centre’s PC pro-
gramme: advanced, incurable cancer; age ≥18 years;
written informed consent; eligible for at least one
follow-up assessment after inclusion. Exclusion cri-
teria were: patients being treated with curative intent;
inability to comply with the study due to psychotic
disorders, severe cognitive impairment or language
problems; imminent death; or inability to come for
follow-up due to medical, social or geographical
reasons.
Ethical considerations
The study was performed according to the
Declaration of Helsinki and was registered in the
ClinicalTrials.gov database (No. NCT01362816).
Ethical approval was obtained at each site.
Statistical analyses
Standard descriptive statistics, χ2 tests and one-way
ANOVAs were used to compare subgroups for the
web survey and patient data as appropriate. Data from
ESAS-r are presented as mean scores (SD) and cate-
gorised severity: 0–3=none/mild, 4–6=moderate and
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7–10=severe. The significance level was set at
p<0.05. The ANOVA analyses were corrected for
multiple comparisons using Bonferroni adjustments,
with a resulting p<0.00625. Dunnett’s T3 or Tukey’s
post hoc tests were performed to test for differences
in patient characteristics between centre categories.
The ANOVAs were performed with the predefined
four centre categories: cancer centres with PC beds,
without PC beds, regional hospitals and hospices/
nursing homes and also repeated using the following
three categories: centres with PC beds, without PC
beds and hospices/nursing homes. Survival was cate-
gorised in days <30, 30–89, 90–149, 150–179 with
the latter category representing 6 months survival or
longer. Sample size calculations were not performed
as this was not a hypothesis-testing study. IBM SPSS
Statistics V.20.0 for Windows (IBM Corporation,
Armonk, New York, USA) were used for data analysis.
RESULTS
The web survey
Thirty-seven centres completed the web survey; the
30 centres that included patients presented were
across 12 countries: Australia, Belgium, Canada,
Denmark, Georgia, Germany, Italy, Norway, Portugal,
Spain, Switzerland and the UK. The study ran from
April 2011 through October 2013.
Table 1 shows characteristics of the participating
centres, 27 European, 1 Australian, 2 Canadian. The
majority, 24/30 (80%), were hospitals, in addition to
four hospices, one nursing home and one PC home
care service. Most centres (18/30, 60%) had rural and
urban catchment areas; the remaining 40% covered
urban areas.
Sixteen (67%) of the participating hospitals had
designated inpatient PC beds, 28 (98%) had PC out-
patient units and 25 (83%) had PC teams. A patient
hotline for contact and questions was available in 19
(63%) centres. The annual number of PC patients
treated ranged from 113 to 729, and 13 (43%)
centres reported that patients with cancer constituted
90% or more of their PC patients.
State and/or community funding was predominant
(26/30). Almost all centres (28/30) had easy access to
general medicine or oncology inpatient units (26/30),
as well as diagnostic facilities such as basic radiology
(27/30), MRI (24/30), CT (24/30) and PET (16/30)
scans. Twenty centres had chemotherapy and radio-
therapy as part of their PC programmes, while one
provided radiotherapy only. This was supplemented
with other anti-cancer therapies such as targeted
therapy, hormonal treatment and immunotherapy in
12 centres, while 9 centres did not provide any
anti-cancer therapy. The average length of stay
reported by the centres with inpatient PC beds varied
from 7 to 73 days.
In all but three centres, the PC programme was led
by a physician, two heads had a nursing background,
while one centre had a joint physician/nurse leader-
ship. In 8 of the 30 centres, the lead practitioner had
specialist PC training (seven physicians, one nurse). As
per table 1, the number of physicians with specialist
training and presence of physicians and nurses varied
within the programmes. Physicians were physically
available 24/7 in 17 of the 30 centres and on phone
in 23/30 centres, while the corresponding numbers
for nurses were 19/30 and 16/30 centres, respectively.
Several other professions were also part of all PC pro-
grammes, most often social workers (n=15), psychol-
ogists and physiotherapists (n=12, both).
Professorships were present in 15 of the 30 PC pro-
grammes, varying from 0.2 to 3 full-time equivalents
(table 1); 13 had a medical background. Academic
positions, defined as research staff not doing clinical
work, were present in 15 centres, varying from 0.3 to
8 full-time equivalents (senior researchers, PhD/master
students). Two of the six centres in the hospice-
nursing home category had part-time professorships.
Patient characteristics
Of the 1739 patient records, 41 were not included in
the analyses, as the HCP (n=31) or patient CRFs
(n=9) or both (n=1) were not completed at inclusion.
Records with occasional missing values for single vari-
ables were retained, leaving a study sample of 1698
patients. Most patients, 46% (n=778), were included
at hospital PC services, followed by general oncology
departments (35%). Sixty-one per cent (n=1017)
were outpatients.
The median age was 66 (range 21–97), and 50.2%
were females (table 2). The mean MMSE score on the
0–5 scale was 4.5 (SD 0.9), with 29% having a score
below 4, suggesting a degree of cognitive failure.18 The
predominant diagnoses were gastrointestinal (31%),
lung (20%) and breast cancer (17%). One or more
comorbid conditions were reported in 60%, with heart
disease being most common (28%; table 2).
Eighty-three per cent had disseminated or metastatic
disease, with bone (37%), liver (30%) and lung (30%)
metastases being most frequent.
Anti-cancer therapy was received by 1015 patients
(60%) at inclusion: chemotherapy (n=707/42%) and
hormonal therapy (n=172/10%; table 2). Twenty-seven
per cent of patients who died between 1 and 3 months
after inclusion and 15% of those who died within
30 days from inclusion received chemotherapy at
study entry. Fifty-nine per cent (n=991) were using
opioids at baseline: this was sole analgesic therapy in
20% (198), combined with other analgesics in 793
(80%). Anti-depressants to treat depression were used
by 16%.
A total of 1060 patients (62%) died during
follow-up. Survival length for the 1035 patients with
a verified date of death is categorised in table 2 and
shows that 68% of these died within 6 months from
inclusion.
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Table 1 Centre characteristics*
Institution name Country Institution type†
Number of
PC-beds
Professional background
of head of PC
programme
Physician specialists
in the PC
programme‡
Availability
of physicians
Availability
of nurses
Professors
in the PC
programme
Research staff
in the PC
programme§
Southern Adelaide Palliative Services,
Adelaide, South Australia
AU Cancer centre with
inpatient PCU
15 Psycho-oncology nursing PC spec: 2.5 Respiratory
med: 0.6
24/7 24/7 Yes Yes
University Hospital, Ghent BE Cancer centre with
inpatient PCU
6 Anaesthesiol. Anesth.: 0.8 Daytime/5 Daytime/5 Yes –
Comprehensive Cancer Centre, Vratsa BG Cancer centre with
inpatient PCU
15 Anaesthesiol. Oncol.: 0.5
Anaesth..: 1
Surgery: 0.3
IntMed: 0.5
24/7 24/7 – –
Cross Cancer Institute, Northern
Alberta
CA Cancer centre without
inpatient PCU
– PC specialist Oncology Oncol: 5
GP: 13
24/7 24/7 Yes** Yes
The Edmonton Zone Palliative Care
Program, Alberta
CA Cancer centre with
inpatient PCU
22 PC specialist GP: 13 24/7 24/7 Yes** –
Cantonal Hospital, St. Gallen CH Cancer centre with
inpatient PCU
26 Oncology Internal Med. Oncol.: 2.7
IntMed.: 4.3
24/7 24/7 Yes Yes
Kantonsspital Graubünden, Chur CH Regional hospital with
inpatient PCU
8 PC specialist IntMed: 1 Daytime/5 24/7 Yes
Rigshospitalet, Copenhagen DK Regional hospital – Oncology Oncol.: 1
Anaesth.: 1
24/7 Daytime/5 Yes Yes
Bispebjerg Hospital, Copenhagen DK Regional hospital with
inpatient PCU
12 Oncology Oncol: 1
Anaesth. 2
24/7 Daytime/5 – Yes
Hospital Universitario Arnau de
Vilanova, Lleida
ES Regional hospital – GP GP: 2 Daytime/5 Daytime/5 – Yes
Clínica Universidad de Navarra,
Pamplona
ES Cancer centre without
inpatient PCU
– Radiation oncology Oncol.: 1
GP: 1
Daytime/5 Daytime/5 –
Hospital Centro de Cuidados Laguna,
Madrid
ES Hosp-nursing-home 43 GP GP: 6.4 24/7 24/7 – Yes
Institut Catala D’Oncologia, Barcelona ES Cancer centre with
inpatient PCU
18 Internal Med. Oncol.: 1
Anaesth.: 0.5
IntMed.: 1
GP: 2
Geriatrician: 4
Daytime/5 24/7 – Yes
Cancer Prevention Centre (CPC), Tblisi GE Cancer centre with
inpatient PCU
22 PC specialist Oncology Oncol.: 3
Surgery 1
GP: 8
24/7 24/7 Yes Yes
Fondazione IRCCS Istituto Nazionale
dei Tumori, Milan
IT Cancer centre with
inpatient PCU
10 Neurology Oncol.: 2 Anaesth.:1 Daytime/5 24/7 Yes
Continued
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Table 1 Continued
Institution name Country Institution type†
Number of
PC-beds
Professional background
of head of PC
programme
Physician specialists
in the PC
programme‡
Availability
of physicians
Availability
of nurses
Professors
in the PC
programme
Research staff
in the PC
programme§
Hospital of Piacenza, Piacenza IT Regional hospital with
inpatient PCU
12 Oncology Oncol.: 1 Anaesth.:1
IntMed.: 0.5
GP: 0.5
24/7 24/7 Yes Yes
Hospice Villa Speranza, Rome IT Hosp-nursing-home 621 Oncology Oncol.: 2.5 Surgery: 1
IntMed.: 2
GP: 1
24/7 Daytime/5 Yes –
Istituti Clinici di Perfezionamento
Hospital, Milan
IT Regional hospital – Anaesthesiol. Oncol.: 0.5
IntMed.: 0.5
Daytime/5 Daytime/7 – –
U.O. Complessa Cure Palliative e
Terapia del Dolore Istituti Clinici di
Perfezionamento, Milan
IT Cancer centre without
inpatient PCU
– Anaesthesiol./Oncology Oncol.: 0.3
Surgery: 0.2
IntMed.: 0.5
Daytime/7 Daytime/5 – –
University of L’Aquila, L’Aquila IT Regional hospital with
inpatient PCU
4 Oncology/neurology+nursing Oncol.: 3 Neurol: 0.3 24/7 24/7 Yes –
Arcispedale Santa Maria Nuova Reggio
Emilia
IT Regional hospital – Oncology Oncol.: 1 Daytime/5 Daytime/5 – –
St. Olavs University Hospital,
Trondheim
NO Cancer centre with
inpatient PCU
12 Oncology Oncol: 2.5
GP: 1
24/7 24/7 Yes Yes
Oslo University Hospital, Oslo NO Cancer centre with
inpatient PCU
8 Oncology Anesth. 3
IntMed.: 1
GP: 1
Gynaecol: 1
24/7 24/7 Yes Yes
Haraldsplass Deaconess Hospital,
Bergen
NO Regional hospital with
inpatient PCU
8 Anaesthesiol. Anaesth. 2
IntMed.: 1
GP: 1
24/7 24/7 Yes Yes
Øya Community Hospital, Trondheim NO Hosp-nursing-home§ 8 GP GP: 0.3 Daytime/5 24/7 – –
Instituto Português de Oncologia de
Lisboa Francisco Gentil, EPE, Lisbon
PT Cancer centre without
inpatient PCU
– Internal Med. IntMed.: 2 Daytime/5 Daytime/5 – –
St Gemmas Hospice, Leeds UK Hosp-nursing-home 32 PC nurse specialist – Daytime/5 24/7 Yes –
West Lothian Community Specialist
Palliative Care Team, Edinburgh
UK Hosp-nursing-home – PC specialist – 24/7 Daytime/5 – –
Nottingham University Hospitals,
Nottingham
UK Cancer centre with
inpatient PCU
20 PC specialist PC spec.: 4
Anaesth.: 0.1
Daytime/5 24/7 – Yes
Marie Curie Cancer Care Glasgow
Hospice, Glasgow
UK Hosp-nursing-home 30 PC specialist – 24/7 24/7 – –
*Information in web survey based on data from 2010.
†Four categories: cancer centre with inpatient PCU (palliative care unit), cancer centre without inpatient PCU, Regional hospital, Hospice, nursing-home, hospice at home.
‡Numbers refer to full-time equivalents.
§Defined as persons doing research, not clinical work, including senior researchers, PhD candidates and Master students.
**Joint professorship.
AU, Australia; Anaesthesiol/anaesth., Anaesthesiology; BE, Belgium; BG, Bulgaria; CA, Canada; CH, Switzerland; DE, Denmark; ES, Spain; GE, Georgia; GP, General practitioner; Gynaecol, Gynaecologist; IntMed, Internal
Medicine; IT, Italy; NO, Norway; Oncol, Oncology; PCU: Palliative care unit; PT, Portugal.
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Table 3 displays the patients’ mean scores on phys-
ical functioning, pain and ESAS. Mean scores above
3.0 were found with tiredness (4.3 SD 3.0), drowsi-
ness (3.1 SD 2.9) and well-being (3.6 SD 2.7), and for
average and worst pain intensity past 24 hours (3.2
SD 2.7 and 4.0 SD 3.3). ESAS scores ≥7, indicating
severe symptom intensity, varied from 4% in nausea
to 27% with tiredness, relative to 15% and 27% for
average and worst pain intensity, respectively.
Thirty-seven per cent confirmed episodes of BTP
during the past 24 hours (table 3).
Table 4 displays selected medical and patient-
reported variables grouped by four centre categories:
cancer centres with (n=11) and without inpatient
PCUs (n=4), regional hospitals (n=9) and hospices/
nursing homes (n=6).
Overall, patients included from the hospice/nursing
home category were significantly older, less likely to
receive chemotherapy, had poorer physical perform-
ance and reported significantly more tiredness com-
pared with patients in the other three centre
categories (p values 0.03 to <0.001). Their survival
time from inclusion was also significantly shorter
(p<0.001; table 4). Five of the regional hospitals had
PCUs with inpatient beds, and one could argue that it
may be arbitrary to differentiate between cancer
Table 2 Patient characteristics at inclusion
Variable
N=1698,
n (%) Missing, n
Gender 0
Female 852 (50.2)
Male 846 (49.8)
Education (years) 20
<10 544 (32)
10–12 700 (42)
>12 434 (26)
Living situation 7
Alone 349 (21)
With spouse/partner 737 (43)
With spouse/partner and children 376 (22)
With others (children or adults) 210 (13)
In an institution 19 (1)
Country 0
Australia, 1 site 35 (2)
Belgium, 1 site 95 (6)
Bulgaria, 1 site 28 (2)
Canada, 2 sites 94 (6)
Denmark, 2 sites 100 (6)
Georgia, 1 site 19 (1)
Italy, 7 sites 605 (35)
Norway, 4 sites 235 (14)
Portugal, 1 site 58 (3)
Spain, 4 sites 233 (14)
Switzerland, 2 sites 68 (4)
UK, 4 sites 128 (7)
Treatment setting 38
Inpatients 348 (21)
Outpatients 1017 (61)
Home care 295 (18)
Comorbidity (numbers) 5
0 679 (40)
1 638 (39)
2 283 (16)
3 or more 93 (5)
Primary cancer diagnosis* 4
Digestive organs 520 (31)
Respiratory organs† 343 (20)
Breast cancer 284 (17)
Male genital organs 126 (7)
Gynaecological 99 (6)
Urinary 75 (4)
Head 58 (4)
Leukaemia or lymphoma 44 (3)
Malignant connective/soft-tissue tumours 40 (2)
Skin cancer/malignant melanoma 36 (2)
CNS tumours 24 (1)
Secondary/ill-defined malignant tumours 24 (1)
Malignant endocrine tumours 11 (1)
Other‡ 10 (1)
Continued
Table 2 Continued
Variable
N=1698,
n (%) Missing, n
Disease status 8
Metastatic/disseminated 1414 (83)
Local/locally advanced 276 (17)
Survival, days from inclusion 663§
<30 151 (15)
30–89 299 (29)
90–149 184 (18)
150–180 67 (6)
>180 334 (32)
Treatment with chemotherapy at inclusion 3
Yes 707 (42)
No 998 (58)
Treatment with chemotherapy by the survival
group (days)
<30 23 (15)
30–89 80 (27)
90–149 85 (46)
150–180 26 (39)
>180 162 (49)
Treatment with opioids at inclusion 22
Yes 991 (59)
No 685 (41)
*Based on ICD-10 diagnoses from patient records.
†Including eight patients with laryngeal cancer.
‡Including malignant bone tumours (n=8), multiple primary cancers (n=2).
§Incl. 25 patients reported dead, but with no date registered.
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centres and regional hospitals with inpatient PCUs.
Thus, the analyses were repeated with three centre
categories: hospitals with (n=16) and without PC
beds (n=8) and hospices/nursing homes (n=6), yield-
ing similar results (data not tabulated).
DISCUSSION
This is the first study to characterise PC services and
patients across a wide range of centres and countries.
There were differences and similarities in organisa-
tional issues, number of physician specialists, academic
affiliations and research activities across the participat-
ing centres. Most centres had outpatient clinics, easy
access to general medicine or oncology units, and
83% had in-house PC teams. Cancer was the predom-
inant disease within the PC programmes, and
one-third offered chemotherapy and radiotherapy as
part of their programme. All centres reported that
their PC teams were multidisciplinary, although the
size and composition varied.
Overall, patient characteristics based on the HCP
registrations correspond to findings from other studies
in PC or advanced cancer regarding the most common
diagnoses, about 60% receiving opioids,21–23 and a
median age around 66 years,5 24 albeit higher than
some studies.25 26 Mean scores on the self-reported
symptoms on the ESAS resembled previous reports,
with tiredness being most pronounced.19 21 24 It is
noteworthy, however, that the mean pain score on the
ESAS was <3, with only 8% scoring in the upper
range (≥7), whereas the mean scores on the average
and worst pain items of the BPI exceeded 3, with 15%
and 27% of patients reporting high pain intensity (≥7).
This may indicate suboptimal pain treatment, still a
persistent problem.27 It does once again underline the
necessity to use different time windows when assessing
pain intensity. A prevalence of BTP of 37% is lower
than the 50% reported in a review presenting pooled
analyses of the BTP literature.28 Without a more thor-
ough assessment, it is difficult to ascertain if this
reflects true BTP or end-of-dose failure of medication.
Patient characteristics differed when compared
across our four predefined categories of participating
centres (table 4), and the same differences remained
significant when using a three-centre categorisation.
The 233 patients within the hospice/nursing home
services had a significantly shorter survival, reported
significantly more tiredness, were more often receiv-
ing opioids and were less prone to get chemotherapy,
compared to hospital patients. The fact that 42% of
patients overall were receiving anti-cancer treatment
on inclusion may in part be explained by the fact that
Table 3 Patient self-report of symptoms and physical functioning
N=1698
Variables Mean SD Missing
N
0–3
%
0–3
N
4–6
%
4–6
N
7–10
%
7–10
Pain* 2.1 2.3 14 1246 (74) 308 (18) 141 (8)
Tiredness* 4.3 3.0 13 654 (41) 541 (32) 450 (27)
Nausea* 1.0 2.1 21 1471 (88) 138 (8) 68 (4)
Depression* 2.5 2.9 17 1144 (68) 318 (19) 219 (13)
Anxiety* 2.3 2.8 18 1183 (70) 315 (19) 192 (11)
Drowsiness* 3.1 2.9 31 994 (60) 396 (23) 277 (16)
Appetite* 3.0 3.2 23 1322 (78) 240 (14) 128 (8)
Well-being* 3.6 2.7 35 837 (50) 552 (33) 274 (17)
Shortness of breath* 1.8 2.5 14 1320 (78) 238 (14) 26 (8)
Pain intensity, average past 24 hours† 3.2 2.7 9 991 (59) 449 (26) 249 (15)
Pain intensity, worst, past 24 hours† 4.0 3.3 21 796 (47) 418 (25) 463 (27)
Physical functioning‡ 64.3 29.2 14
N
yes
%
yes
PHQ9 depression§ 339 (20) 28
Anhedonia 553 (32) 33
Depressed mood 437 (26) 30
Neuropathic pain¶ 560 (34) 65
Breakthrough pain last 24 hours** 608 (37) 44
*ESAS-r: 0–10 scale, higher score implies higher symptom intensity/poorer well-being, ‘right now’.19
†BPI: 0–10 scale, higher score implies higher pain intensity.15
‡QLQ-C15-PAL: 0–100 scale, higher score implies better functioning.20
§PHQ9: ‘yes’ indicates a score of 2 or 3 on the 0–3 scale assessing the frequency at which people have been bothered by anhedonia (little interest or
pleasure in doing things) and depressed mood during the past 2 weeks: 2=‘more than half the days’ and 3=‘nearly every day’.18
¶‘Does the skin in the painful area feel different from normal, more numb or more sensitive?’: yes/no, adapted from PainDetect.16
**‘Have you had flare-ups of breakthrough pain in the last 24 hours?’: yes/no, adapted from the Alberta Breakthrough Pain Assessment Tool.17
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the majority (70%) were outpatients, which may
reflect a healthier subset of PC patients. This is
further substantiated with longer survival among
those receiving chemotherapy (table 2), but may also
indicate that integration between oncology and PC is
slowly emerging, with more emphasis on symptom
control.
Cancer centres with or without inpatient PCUs
recruited >50% of the patients (table 4), Thus, it may
be speculated that anti-cancer treatment was adminis-
tered closer to the end of life in these centres than,
for example, in smaller regional hospitals, as
reported.29 However, the use of anti-neoplastic
therapy in an acute PCU was investigated26 and it was
concluded that this was limited to a small percentage
of patients and was associated with characteristics
such as younger age, female sex and cancer diagnoses,
similar to findings in a Norwegian study.30
The ongoing discussion about chemotherapy
towards the end of life is important as intensive
treatment at this stage has been associated with poorer
quality of life.6 31 32 In this study, 15% who died
within 1 month after inclusion received chemotherapy,
relative to 10% and 18% in other studies.30 33 These
numbers still indicate a need for discussion and a
potential for improvement. Even if conclusions about
potential overtreatment cannot be drawn from this
study, the percentages receiving chemotherapy seem
relatively high. Although the numbers were small
when split by centre categories, we found that the
lowest proportion of patients getting chemotherapy
during the last month was in the hospice/nursing
home category (4%), as expected, second to patients
from cancer centres with PCUs (14%; table 4). This
may be because patients in the latter category were
recruited from PCUs, rather than from general oncol-
ogy units, implying that the principles of good PC
with optimal symptom management were in the fore-
front, and probably that the prognostication accuracy
was better.
Table 4 Patient characteristics, grouped by centre types*
Cancer centre
with PCU†
N=11
Cancer centre
without PCU†
N=4
Regional hospital
N=9
Hospice,
nursing-home‡
N=6
p ValueN (%) N (%) N (%) N (%)
No. of patients 666–685 (97–100) 234–230 (98–100) 546–534 (98–100) 233–224 (96–100)
Chemotherapy at inclusion 272 (39.8) 119 (50.9) 290 (53.1) 26 (11.3) <0.001§
Using opioids 392 (58.2) 136 (58.4) 311 (57.3) 152 (67.3) 0.06§
Breakthrough pain¶ 252 (37.8) 77 (33.5) 207 (38.8) 72 (32.0) 0.22§
PHQ9, depression** 136 (20) 45 (20) 104 (19) 54 (24) 0.53§
Survival (days)
Missing 237
n=448
Missing 119
n=115
Missing 278 n=268 Missing 29 n=204 <0.001§
<30 58 (12.9) 8 (7.0) 36 (13.4) 49 (24.0)
30–89 132 (29.5) 27 (23.5) 63 (23.5) 77 (37.7)
90–149 86 (19.2) 22 (19.1) 48 (17.9) 28 (13.7)
150–180 31 (6.9) 13 (11.3) 15 (5.6) 8 (3.9)
>180 141 (31.5) 45 (39.1) 106 (39.6) 42 (20.6)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) p Value††
Age (years) 63.7 (12.2) 64.8 (11.9) 65.6 (12.0) 73.1 (11.5) <0.001
Karnofsky score 68.7 (15.5) 71.6 (13.2) 68.4 (17.0) 55.4 (15.1) 0.03
Average pain intensity‡‡ 3.1 (2.6) 3.2 (2.7) 3.2 (2.9) 3.2 (2.7) 0.95
Worst pain intensity‡‡ 3.9 (3.2) 4.3 (3.5) 3.7 (3.2) 4.0 (3.2) 0.84
Tiredness§§ 4.0 (2.8) 4.5 (2.9) 4.5 (3.1) 5.0 (3.0) <0.001
Drowsiness§§ 3.3 (2.8) 2.8 (3.1) 2.8 (2.9) 3.3 (3.0) 0.01
Well-being§§ 3.8 (2.5) 3.8 (2.8) 3.5 (2.8) 3.7 (2.8) 0.32
Physical functioning¶¶ 66.7 (28.2) 72.1 (25.4) 67.8 (27.1) 44.3 (31.6) <0.001
*Grouped according to information given on the web survey.
†PCU: palliative care unit with inpatient beds.
‡Including one hospice at home-service.
§χ2 tests for categorical variables.
¶‘Have you had flare-ups of breakthrough pain in the last 24 hours?’=yes, adapted from the ABPAT.17
**Presence of PHQ9 depression=yes, indicates a score of 2 or 3 on the 0–3 scale assessing the frequency at which people have been bothered by
anhedonia (little interest or pleasure in doing things) and depressed mood during the past 2 weeks: 2=‘more than half the days’ and 3=‘nearly every
day’.18
††One-way ANOVAs after correcting for multiple comparisons using Bonferroni adjustments.
‡‡BPI 0–10 scale, higher score implies higher pain intensity.15
§§ESAS-r: 0–10 scale, higher score implies higher symptom intensity/poorer well-being.19
¶¶QLQ-C15-PAL: 0–100 scale, higher score implies better functioning.20
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An important issue arising from this study relates to
the representativity of the patient sample. Recruitment
of centres was based on self-selection, and most insti-
tutions were hospitals and provided anti-cancer treat-
ment as part of their PC programmes. Furthermore,
50% of centres, also including hospices, had an aca-
demic affiliation in the form of professorships and/or
personnel doing research. Most centres with academic
affiliations or with stakeholders involved with inter-
national networks have an obligation to do research
and probably also receive some funding to do so. This
is in contrast to smaller community-based centres pro-
viding PC to groups of patients with other medical
and sociodemographic characteristics. On the other
hand, our results point to a tendency towards more
academia in PC overall and a high level of compe-
tence, although university affiliations vary throughout
Europe.8 Research is necessary to fulfil the obligation
of improving the quality, competence and access to
PC, as emphasised in the EU declaration on PC.10
Thus, efforts must be taken to optimise the generalis-
ability of research findings. Routine data collections
may be useful,34 and the registration of non-
participants in studies provides a more complete
picture of PC patients.21 35 Another recommendation
is related to the need for a standardised, uniform
description of patient characteristics, a shortcoming
that has been addressed for decades.36 37 Thus, a
major strength of this study is the use of an early
version of the recently published EAPC basic data
set,11 consisting of a minimum set of basic sociodemo-
graphic and medical variables, supplemented by
patients’ self-reported symptoms.
Further, it is noteworthy that most centres had easy
access to general oncology and diagnostic facilities
and that 35% of patients were recruited from general
oncology units, even if treatment within a PC pro-
gramme was an explicit inclusion criterion. This may
be taken to indicate an integration between general
oncology and PC, a frequently addressed issue3 38
since the Temel study in 2010,6 although a global con-
sensus on what constitutes integration is lacking.39 It
should be remembered, however, that this study did
not aim to explore the integration of oncology and
PC per se.
It may be argued that our study is primarily a
hospital-based study, as there were few other types of
settings. As can be inferred from the results, there
were many similarities between the hospital settings.
However, since permission and access to patients for
research purposes vary across and within centres, we
did not specifically investigate potential differences
between cancer centres and regional hospitals. To get
valid results on this, a much more detailed character-
isation of centres is necessary that was not feasible in
a large-scale study like this.
Some limitations apply. First, comparing patient
data across institutions is difficult, and it could be
argued that another categorisation of centres may
have given different results. On the other hand,
results were relatively similar when analyses were per-
formed with four and three categories, respectively,
and significant differences were found when compar-
ing hospices/nursing homes with the other categories.
It should also be remembered that the results are
based on quantitative data and do not purport to
evaluate the quality of care. The relatively high per-
centage of potential cognitive deficits (29%) may be
attributed to the use of the 4-item MMSE version13
that lacks sufficient validation, although correspond-
ing with other results.40 Some centres performed a
consecutive sampling, whereas others recruited a con-
venience sample due to shortage of staff. Ideally, iden-
tical procedures should have been followed
everywhere, although a complete standardisation is
difficult as collaborators may have restricted access to
patients. However, with more than 1600 patients, we
believe that the sampling strategy did not introduce a
substantial bias, compared to other studies in PC or
advanced cancer, although it cannot be ruled out that
the frailest patients were not included.21 35
The study’s strengths are related to the participation
from countries throughout Europe and beyond, repre-
senting a variety of settings that recruited more than
50 PC patients from general and specialised units, the
large sample size, the use of well-known assessment
tools and the simultaneous registration of patient and
organisational data.
The findings from this study are helpful in inform-
ing our research agenda for future work. It is clear
that heterogeneity exists, and therefore detailed char-
acterisation in future work is imperative to facilitate
comparison. We argue that there is a need to conduct
prospective studies with consecutive sampling of
patients who are well characterised with patient-
reported outcome measures and objective ratings by
HCPs that seek to further define the patient popula-
tion and needs in advanced cancer. This is an import-
ant step as the increasing cancer incidence and the
exponential increase in the elderly means that more
PC services will be outside of specialised institutions
and more likely to be in non-specialist settings, par-
ticularly primary care.
CONCLUSION
The wide variation in PC services and patients across
Europe is essential as it enables a true picture of PC
with implications for the development of services,
research and funding. It is encouraging that the advo-
cated approach of integrated oncology and PC is
being realised in many centres. The high level of
research activities provides grounds for optimism that
PC, traditionally regarded as a having a paucity of evi-
dence supporting practice, is attempting to change
this by integrating research. We propose that future
studies provide thorough descriptions of PC
Research
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organisation and case mix to increase the generalis-
ability of PC research.
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